Abstract
Valproate is extensively metabolized in the liver and at least six main pathways which produce about 50 metabolites have been identified in man. The enzyme-inducing antiepileptic drugs phenobarbital, primidone, phenytoin and carbamazepine increase total valproate clearance by 30–85%, whereas cimetidine and the new anticonvulsant compound striripentol display a small inhibitory effect (10–20%). Both carbamazepine and phenytoin induce a two-fold increase in the formation of Δ4-valproate and stimulateω-oxidation andω-1-oxidation. Acetylsalicylic acid causes a fall of 60–70% in the content in the urine of the metabolites of theβ-oxidative pathway,i.e. Δ 2-valproate, 3-OH-valproate and 3-oxo-valproate, and an increase of glucuronidation (approximately 30%) andδ-dehydrogenation (approximately 20%). Stiripentol inhibits the formation clearance ofΔ 4-valproate by 30%. In the light of the possible therapeutic and toxic effects of some valproate metabolites, drug interactions with valproate at metabolic level may have important clinical implications.
Similar content being viewed by others
References
Gugler R, Von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980;5:67–83.
Loscher W. Concentration of metabolites of valproic acid in plasma of epileptic patients. Epilepsia 1981;22:169–78.
Nau H, Wittfoht W, Schafer H, Jakobs C, Rating D, Helge H. Valproic acid and several metabolites. Quantitative determination in serum, urine, breast milk and tissues by gas chromatography—mass spectrometry using selected ion monitoring. J Chromatogr 1981;226:69–78.
Granneman GR, Wang SI, Machinist JM, Kesterson JW. Aspects of the metabolism of valproic acid. Xenobiotica 1984;14(5):375–87.
Nau H, Loscher W. Valproic acid and metabolites. Pharmacological and toxicological studies. Epilepsia 1984;25:S14–22.
Baillie TA. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem Res Toxicol 1988;1:195–9.
Semmes RLO, Shen DD. Comparative pharmacodynamics and brain distribution ofE-2, valproate and valproate in rats. Epilepsia 1991;32(2):232–41.
Baillie TA, Rettenmeier AW. Valproate biotransformation. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989:601–19.
Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. Cytochrome P-450-catalyzed formation of 4-ene-VPA a toxic metabolite of valproic acid. Science 1987;235:890–3.
Rettenmeier AW, Gordon WP, Prickett KS, Levy RH, Cockard JS, Thummel KE, et al. Formation and elimination of 4-ene-valproic acid, a toxic metabolite of valproate [abstract]. Epilepsia 1986;27(5):591.
Sackellares JC, Sato S, Dreifuss FE, Penry JK. Reductions of steady-state valproate levels by other antiepileptic drugs. Epilepsia 1981;22:437–41.
De Wolff FA, Peters ACB, Van Kempen GM. Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate. Neuropediatrics 1982;13:10–3.
Pisani F, Fazio A, Artesi C, Oteri G, Pisani B, Romano F, et al. An epidemiological study of the clinical impact of pharmacokinetic anticonvulsant drug interactions based on serum drug level analysis. Ital J Neurol Sci 1987;8:135–42.
Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole and multidrug therapy. Ther Drug Monitor 1986;8:411–6.
Henricksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate. A 5 year followup study in 100 children with epilepsy. Acta Neurol Scand 1982;65:504–23.
Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401–10.
Fischer JH, Cloyd JC, Kriel RL, Kraus DM. Effects of age and concomitant antiepileptic drug (AED) therapy on valproic acid (VPA) protein binding and intrinsic clearance (CL-int) in children [abstract]. Epilepsia 1986;27(5):591.
Perucca E, Gatti G, Frigo GM, Crema A, Calzetti S, Visintini D. Disposition of sodium valproate in epileptic patients. Br J Pharmacol 1978;5:495–9.
Bowdle TA, Levy RH, Cutler RE. Effects of carbamazepine on valproic acid kinetics in normal subjects. Clin Pharmacol Ther 1979;26(5):629–34.
Redenbaugh JE, Sato S, Penry JK, Dreifuss FE, Kupferberg HJ. Sodium valproate. Pharmacokinetics and effectiveness in treating intractable seizures. Neurology 1980;30:1–6.
Cloyd JC, Kriel RL, Fischer JH, Sawchuk RJ, Eggerth RM. Pharmacokinetics of valproic acid in children. I. Multiple antiepileptic drug therapy. Neurology 1983;33:185–91.
Grimaldi R, Lecchini S, Crema F, Perucca E.In vivo plasma protein binding interaction between valproic acid and naproxen. Eur J Drug Metab Pharmacokinet 1984;9(4):359–63.
Viswanathan CT, Levy RH. Plasma protein binding interaction between valproic acid and salicylic acids in rhesus monkeys. J Pharm Sci 198;70:1279–81.
Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377–99.
Farrell K, Orr JM, Abbott FS, Ferguson S, Sheppard I, Godolphin W, et al. The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children. J Pediatr 1982;101:142–4.
Orr JM, Abbott FS, Farrell K, Ferguson S, Sheppard I, Godolphin W. Interaction between valproic acid and aspirin in epileptic children. Serum protein binding and metabolic effects. Clin Pharmacol Ther 1982;31(5):642–9.
Abbott FS, Kassam J, Orr JM, Farrel K. The effect of aspirin on valproic acid metabolism. Clin Pharmacol Ther 1986;40(1):94–100.
Schobben F, Vree TB, Van der Kleijn E. Pharmacokinetics, metabolism and distribution of 2-n-propyl pentanoate (sodium valproate) and the influence of salicylate comedication. In: Meinardi H, Rowan AJ, eds. Advances in epileptology. Amsterdam: Swets & Zeitlinger, 1978:271–7.
Vincent JC. Stiripentol. In: Pisani F, Perucca E, Avanzini G, Richens A, eds. New antiepileptic drugs. Epilepsy Res 1991; (Suppl 3):196.
Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Pharmacokinet Drug Dispos 1990;48:225–35.
Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJ. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol 1984;27:341–3.
Kondo T, Otani K, Hirano T, Kaneko S, Fukushima Y. The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid. Br J Clin Pharmacol 1990;29:116–9.
Abbott F, Panesar S, Orr J, Burton R, Farrell K. Effect of carbamazepine on valproic acid metabolism. Epilepsia 1986;27:591.
Kock KM, Prickett KS, Rettenmeier AW, Baillie TA, Levy RH. Beta-oxidation of valproic acid. II. Effects of fasting, glucose, and clofibrate in rat. Epilepsia 1989;30:790–6.
Coulthard MG. Sodium valproate in the treatment of intractable childhood epilepsy. Dev Med Child Neurol 1975;17:534.
Dreifuss FE. How to use valproate. In: Morselli PL, Pippenger CE, Penry JK, eds. Antiepileptic drug therapy in pediatrics. New York: Raven Press, 1983:223–5.
Jann MW, Fidone GS, Israel MK, Bonadero P. Increased valproate serum concentrations upon carbamazepine cessation. Epilepsia 1988;29:578–81.
Loscher W, Nau H. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther 1983;226:845–54.
Lewandoski C, Klug S, Nau H, Neubert D. Pharmacokinetic aspects of drug effectsin vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-ene-valproic acid in whole embryos in culture. Arch Toxicol 1986;59:239–42.
Nau H. Species differences in pharmacokinetics and drug teratogenesis. Environ Health Persp 1986;70:113–29.
Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 1984;4:1143–52.
Schafer H, Luhrs R. Responsibility of the metabolite pattern for potential side-effects in the rat being treated with valproic acid, 2-propylpenten-2-oic acid, and 2-propylpenten-4-oic acid. In: Levy RH, Pitlick WH, Eichelbaum M, Meijer J, eds. Metabolism of antiepileptic drugs. New York: Raven Press, 1984:73–83.
Sussman NM, McLain LW. A direct hepatotoxic effect of valproic acid. JAMA 1979;242:1173–4.
Zafrani ES, Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982;2:648–9.
Zimmermann HJ, Ishak KG. Valproate-induced hepatic injury: Analyses of 23 fatal cases. Hepatology 1982;2:591–7.
Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities. A retrospective review. Neurology 1987;37:379–85.
Dreifuss FE, Langer DH, Moline KA, Maxwell DE. Valproic acid hepatic fatalities. II. U.S. experience since 1984. Neurology 1989;39:201–7.
Kingsley E, Gray PD, Tolman KG, Tweedale R. The toxicity of the metabolites of sodium valproate in cultured hepatocytes. J Clin Pharmacol 1983;23:178–85.
Lewis JH, Zimmerman HJ, Garrett CT, Rosenberg E. Valproate-induced hepatic steatogenesis in rats. Hepatology 1982;2:870–3.
Kuhara T, Inoue Y, Matsumoto M, Shinka T, Matsumoto I, Kawahara N, et al. Markedly increased oxidation of valproate in fulminant hepatic failure. Epilepsia 1990;31:214–7.
Paganini M, Zaccara G, Moroni F, Campostrini R, Bendoni L, Arnetoli G, et al. Lack of relationship between sodium valproate-induced adverse effects in the plasma concentration of its metabolite 2-propylpenten-4-oic acid. Eur J Clin Pharmacol 1987;32:19–22.
Tennison MB, Miles MV, Pollack GM, Thorn MD, Dupuis RE. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia 1988;29:543–7.
Scheffner D, Konig S. Valproate hepatotoxicity. Lancet 1987;2:389–90.
Lenn NJ, Ellis WG, Wasburn ER, Ruebner B. Fatal hepatocerebral syndrome in siblings discordant for exposure to valproate. Epilepsia 1990;31(5):578–83.
Eadie MJ, Hooper WD, Dickinson RG. Valproateassociated hepatotoxicity and its biochemical mechanism. Med Toxicol 1988;3:85–100.
Scheffner D, Konig ST, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach ST. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29(5):530–42.
Kochen W, Scheider A, Ritz A. Abnormal metabolism of valproic acid in fatal hepatic failure. Eur J Pediatr 1983;141:30–5.
Dreifuss FE. Fatal liver failure in children on valproate. Lancet 1987;1:47–8.
Jeavons PM. Sodium valproate and neuronal tube effects. Lancet 1982;2:1282–3.
Robert E, Guibaud P. Maternal valproic acid and congenital neuronal tube defects. Lancet 1982;2:937.
Bjerkedal T, Czeizel A, Goujard J, Kallen B, Mastrioiacova P, Nevin N, et al. Valproic acid and spina bifida. Lancet 1982;2:1096.
Lindhout D, Meinardi H, Barth PG. Hazards of fetal exposure to drug combinations. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt D, eds. Epilepsy, pregnancy, and the child. New York: Raven Press, 1982:275–81.
Meinardi H, Lindhout D. Teratogencity of antiepileptic drugs. Br J Clin Pract 1983;27 Suppl:37–41.
Kaneko S, Otani K, Fukuschima Y, Ogawa Y, Nomura Y, Ono T, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988;29:45–67.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pisani, F. Influence of co-medication on the metabolism of valproate. Pharmaceutisch Weekblad Scientific Edition 14, 108–113 (1992). https://doi.org/10.1007/BF01962698
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01962698